Business
Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference
Nine Poster Presentations Include New Analyses of SILIQ ® and JUBLIA ® LAV...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology ConferenceNine Poster Presentations Include New Analyses of SILIQ® and JUBLIA®LAVAL, QC / ACCESSWIRE / November 1, 2022 / - Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (\"Bausch Health\") and its dermatology business, Ortho Dermatologics, today announced the presentation of nine posters during the Innovations in Dermatology Conference, which takes place Nov. 3-5, 2022, in Las Vegas, Nev. The presentations will feature new data around JUBLIA® (efinaconazole) Topical Solution, 10%, and SILIQ® (brodalumab) Injection, 210 mg/1.5 mL. There will also be six encore presentations, including analyses of DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, ARAZLO® (tazarotene) Lotion, 0.045%, and the investigational medicine IDP-126 Gel-a combination retinoid, antibacterial and antibiotic topical.\"Continued research around our products is a top priority for us at Ortho Dermatologics to ensure our portfolio meets the needs of patients,\" said Richard Lajoie, vice president and general manager, Ortho Dermatologics. \"At this year's Innovations in Dermatology Conference, we look forward to the opportunity to directly engage with dermatologists and share new data on JUBLIA®, which received the APMA Seal of Approval in December 2021, as well as our biologic psoriasis medication, SILIQ®. \"The complete list of Ortho Dermatologics' poster presentations is as follows:JUBLIA® (efinaconazole) Topical Solution, 10%\"Combination Therapy With Efinaconazole for the Treatment of Toenail Onychomycosis.\" Lipner et al.\"Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US.\" Lipner et al.SILIQ® (brodalumab) Injection, 210 mg/1.5 mL\"Brodalumab Provides Rapid Onset of Therapeutic Response for Patients With Moderate-to-Severe Psoriasis.\" Armstrong et al.\"Long-term Skin Clearance Achieved in Moderate-to-Severe Psoriasis Through Interleukin-17 Receptor A Blockade.\" Lain et al.\"Brodalumab: 4-Year US Pharmacovigilance Report.\" Lebwohl et al.ARAZLO® (tazarotene) Lotion, 0.045%\"Tazarotene 0.045% Lotion for Truncal Acne: Efficacy, Tolerability, and Spreadability.\" Kircik et al.DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%\"Fixed-Combination Halob...